Product Reports Resources Pricing Login Book a demo

BioVersys

Biotech & Life Sciences · Basel, Switzerland · Founded 2010

Privately held Swiss biopharmaceutical company MoreLess

BioVersys is a Swiss pharmaceutical company based in Basel, specializing in the research and development of small molecules targeting antimicrobial resistance (AMR). The company focuses on creating therapies that address bacterial infections through novel modes of action and targets. BioVersys operates in the pharmaceutical and biotech sectors, serving healthcare systems globally by providing solutions to combat the silent pandemic of AMR. The business model revolves around advancing clinical trials and bringing effective treatments to market, thereby generating revenue through the commercialization of its pharmaceutical products. The company is governed by a board of directors with extensive experience in the pharma and biotech industries, ensuring strategic oversight and guidance. BioVersys is committed to improving patient outcomes and safeguarding global health by addressing one of the most pressing medical threats of our time. Keywords: antimicrobial resistance, small molecules, bacterial infections, pharmaceutical, biotech, clinical trials, healthcare, global health, therapies, Basel

Valuation $100–250M
Revenue $1–10M
Headcount <100
Total funding $100–500M
Unlock exact values This page shows ranges. Dealroom has the exact numbers for BioVersys and the history behind them.

Talent graph

BioVersys's talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on BioVersys's cap table

Sourced from Dealroom's funding history.

Seed 2 investors entered at this stage
EVA Basel
CARB-X
Series A 1 investor entered at this stage
Business Angels Switzerland
Series B+ 4 investors entered at this stage
European Investment Bank
AMR Action Fund
GSK
Guangzhou Industrial Investment Fund

Global footprint

Where BioVersys has talent and traffic

Workforce by country
5 countries with
team presence
🇨🇭 Switzerland57.1%
🇫🇷 France32.1%
🇺🇸 United States3.6%
🇩🇪 Germany3.6%
🇬🇧 United Kingdom3.6%
5 countries shown

Market sentiment

What the market is saying about BioVersys

An AI-synthesized read of the highest-engagement posts about BioVersys on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See BioVersys on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.